ACUMEN PHARMACEUTICALS INC. - COMMON STOCK

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

14 May 2024 07:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

13 May 2024 16:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

08 May 2024 17:47:25 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

08 May 2024 08:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

07 May 2024 16:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

16 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease

04 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

26 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting

21 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

19 Mar 2024 16:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

12 Mar 2024 16:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

08 Mar 2024 08:50:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

21 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

01 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

04 Jan 2024 16:15:20 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

13 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

13 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

07 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023

06 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

06 Nov 2023 07:30:00 By Nasdaq GlobeNewswire